Patient Registry of Intrathecal Ziconotide Management(PRIZM)

Inclusion Criteria: * Patient is at least 18 years of age at the time of study entry. * Patient who has severe chronic pain, whom IT therapy is warranted, and who is intolerant of, or refractory to other treatments, such as systemic analgesics, adjunctive therapies, and/or IT morphine. * Patient is planned to be initiated on IT PRIALT as the sole agent in the pump at a participated site. * Patient has not received PRIALT treatment administered continuously via Medtronic SynchroMed® II pump within the past 30 days. * Patient has a life expectancy \>6 months as determined by the physician. * Patient is able to read, understand, and voluntarily sign the IRB-approved informed consent document prior to the performance of any study-specific procedures. * Patient is able to understand and complete required assessments. Exclusion Criteria: * Patient has a known hypersensitivity to PRIALT or any of its formulation components. * Patient has a pre-existing history of psychosis. * Patient has infection at the microinjection site, uncontrolled bleeding diathesis, or known spinal canal obstruction that impairs circulation of cerebrospinal fluid. * Patient is being initiated with PRIALT in conjunction with other IT agents. * Patients with any other concomitant treatment or medical condition that, in the opinion of the clinician, would render IT administration hazardous.